Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
Sponsor: Abramson Cancer Center at Penn Medicine
Summary
Men with a history of prostate cancer may be in this study. Subjects recommended for a prostatectomy or oligometastectomy will undergo PET/CT imaging using a novel radiotracer \[18F\]FTT to evaluate PARP-1 activity in known or suspected sites of primary or metastatic disease. Imaging will be compared with pathology results, including additional research assays when possible.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2017-07-14
Completion Date
2027-02-11
Last Updated
2026-02-20
Healthy Volunteers
No
Conditions
Interventions
[18F]FluorThanatrace
Fluorine-18 labeled FluorThanatrace \[18F\]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is \< 10 μg.
Poly(ADP Ribose) Polymerase 1
Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3.
Locations (1)
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States